跳至主要内容
临床试验/IRCT20160310026998N14
IRCT20160310026998N14招募中3 期

Evaluating the effectiveness of melatonin for the prevention of taxane-induced peripheral neuropathy in patients with breast cancer: A double-blinded randomized clinical trial

Tabriz University of Medical Sciences0 个研究点目标入组 132 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
132

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 85 years(—)
性别
Female

入选标准

  • Patients with breast cancer who are candidate for chemotherapy with taxanes

排除标准

  • History of neuropathy
  • Use of medications that can cause neuropathy such as statins, colchicine, zidovudine, penicillamine, platinum derivatives (cisplatin, oxaliplatin), and vinca alkaloids
  • History of fibromyalgia, rheumatoid arthritis, osteoarthritis, hypothyroidism, sleep apnea, autoimmune diseases, diabetes mellitus, heart failure, myocardial infarction, uncontrolled hypertension, unstable angina, stroke, and seizure in the previous year
  • History of allergy to melatonin
  • Alcohol intake
  • Active infection (such as COVID-19 or other respiratory infections)
  • History of prior chemotherapy
  • Severe kidney or liver failure
  • Presence of other malignancies
  • Prediction of patient nonadherence

研究者

相似试验